New landmark-analysis data presented at NY Valves 2026 show that the early-TAVI advantage seen in the original EARLY TAVR trial persists out to five years, with the death-and-stroke benefit concentrated almost entirely after the two-year mark.
For decades, the default approach to severe aortic stenosis without symptoms has been to wait.
Guidelines have long recommended routine surveillance every six to twelve months until a patient develops dyspnea, angina, syncope, or another qualifying symptom that triggers valve replacement.
That paradigm has been steadily eroding since 2019, and the newest data presented this week push it further still.
What the New Data Show
At a median follow-up approaching five years, patients randomized to early transcatheter aortic valve implantation had a significantly lower rate of the composite of death, stroke, or heart failure hospitalization than those managed with clinical surveillance (15.2% vs 24.2%; HR 0.58, 95% CI 0.43–0.78).
Critically, a landmark analysis starting at the two-year mark found that this advantage was not simply carried forward from early hospitalizations driven by elective valve replacement in the surveillance arm.
Beyond two years, early intervention still carried a lower risk of the composite endpoint (HR 0.65, 95% CI 0.43–0.98), and the death-or-stroke benefit specifically emerged almost entirely in this later window (HR 0.61, 95% CI 0.40–0.94).
In other words, the two strategies tracked together for death and stroke through year two, then diverged.
| Endpoint | Early TAVI | Surveillance | Effect Estimate |
|---|---|---|---|
| Composite: death, stroke, or HF hospitalization | 15.2% | 24.2% | HR 0.58 (0.43–0.78) |
| Composite, landmark from year 2 | — | — | HR 0.65 (0.43–0.98) |
| All-cause death | 10.3% | 12.3% | HR 0.84 (0.57–1.24) |
| Stroke | 4.8% | 7.6% | HR 0.63 (0.37–1.07) |
| Death or stroke | 13.4% | 17.5% | 95% CI for HR, 0.53–1.04 |
| Death or stroke, landmark from year 2 | — | — | HR 0.61 (0.40–0.94) |
| Heart failure hospitalization | 3.5% | 10.3% | HR 0.32 (0.18–0.57) |
| HF hospitalization, landmark from year 2 | — | — | HR 0.61 (0.26–1.42) |
Why the Curves Separate at Two Years
By the two-year mark, roughly three in four patients assigned to surveillance had already crossed over to valve replacement, mostly because they developed symptoms.
That crossover explains why the early heart-failure-hospitalization benefit narrows after year two: once nearly everyone has a valve, the groups converge on that particular outcome.
What does not converge is death and stroke, and one proposed explanation is that the waiting period itself, rather than just the underlying valve disease, accounts for a meaningful share of strokes and deaths in patients left in a hemodynamically stressed, untreated state.
Postulated late mechanisms in the surveillance arm include valve underexpansion at the time of eventual implantation, embolic events related to a heavily calcified untreated valve, new-onset atrial fibrillation, and acute decompensation syndromes that develop once compensatory reserve is exhausted.
Those mechanisms remain hypothesis-generating rather than proven, and a full accounting is expected when the complete 5-year dataset is reported in the next one to two years.
Severe AS Definition and the Decision Pathway
The trial's inclusion criteria are a useful refresher on how "truly asymptomatic" severe AS was operationalized: an aortic valve area of 1.0 cm² or less (or an area index of 0.6 cm²/m² or less) with a mean transaortic gradient of at least 40 mmHg or a peak jet velocity of at least 4.0 m/s, confirmed asymptomatic by a negative treadmill stress test or, in a minority, detailed history alone.
Regulatory and Practice Context
These findings build on a trajectory that began with the original trial publication and culminated in the FDA's 2025 approval of the balloon-expandable transcatheter platform for asymptomatic severe AS, the first such approval in this population.
That approval converted a research question into a bedside option, and it means clinicians can now have a genuine shared-decision conversation about timing rather than defaulting to watchful waiting by guideline inertia alone.
A parallel late-breaking trial in 2024, summarized alongside EARLY TAVR in ACC's meeting coverage, tested whether myocardial fibrosis on MRI could identify asymptomatic patients most likely to benefit from early intervention and found no significant advantage for that imaging-guided strategy, which keeps the EARLY TAVR anatomic and hemodynamic criteria as the more actionable framework for now.
| Trial | Intervention | N / Follow-up | Primary Result |
|---|---|---|---|
| EARLY TAVR | Transfemoral TAVI | 901 pts · 5 yr | 15.2% vs 24.2%, HR 0.58 |
| AVATAR | Surgical AVR | 157 pts · 32 mo | 15.2% vs 34.7%, HR 0.46 |
| RECOVERY | Surgical AVR | 145 pts · 6 yr | CV death 1% vs 15% |
AVR, aortic valve replacement; CV, cardiovascular; HR, hazard ratio; pts, patients.
A 74-year-old man is referred after a routine echocardiogram shows an aortic valve area of 0.9 cm², a mean gradient of 46 mmHg, and a peak velocity of 4.3 m/s, with preserved ejection fraction and no reported dyspnea, angina, or syncope.
A treadmill stress test is negative for symptoms or an abnormal blood-pressure response, confirming truly asymptomatic severe AS, and CT angiography shows favorable transfemoral access with no other contraindication to intervention.
Rather than defaulting to surveillance imaging in six months, the heart team uses the 5-year EARLY TAVR data to frame a shared decision: proceed now with a roughly 9-point absolute reduction in 5-year composite events, or accept surveillance with a high probability of eventual crossover and a residual stroke signal that does not fully resolve even after a valve is later placed.
The patient elects early TAVI and is scheduled within the month.
Practical Takeaways
- The death-and-stroke benefit of early intervention is concentrated after year two, which argues against framing early TAVI as merely "pulling forward" an inevitable procedure.
- Nearly three-quarters of surveillance patients in the trial crossed over to AVR by two years, so a true watch-and-wait strategy in this population is, in practice, a watch-and-convert strategy for most patients.
- Trial eligibility was anchored to age 65 or older, low surgical risk, transfemoral-suitable anatomy, and rigorously confirmed asymptomatic status, so extrapolation to younger, higher-risk, or borderline-symptomatic patients should remain cautious.
- The 5-year dataset is still incomplete, with complete follow-up available in roughly 80% of the TAVI arm and 72% of the surveillance arm, and a fuller report is expected within the next one to two years.
Five-year follow-up reinforces that early TAVI outperforms guideline-recommended surveillance in carefully selected patients with truly asymptomatic severe aortic stenosis, with the death-and-stroke advantage emerging specifically after the two-year mark rather than being an artifact of early crossover.
For patients who meet EARLY TAVR's anatomic, hemodynamic, and risk criteria, this supports offering a heart-team discussion about prompt intervention rather than reflexively scheduling another six-month echocardiogram.
REFERENCES
- EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS. TCTMD. Presented at NY Valves 2026.
- Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2025;392(3):217-227.
- EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS. TCTMD, 2024.
- FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis. TCTMD, 2025.
- EARLY TAVR and EVOLVED: Early Intervention in Patients With Asymptomatic AS? American College of Cardiology, 2024.
- AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients. TCTMD, 2021.
- Early Surgery Beats a Conservative Approach in Asymptomatic AS: RECOVERY. TCTMD, 2019
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.